24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids

European Respiratory Journal

Volumn 40, Issue 3, 2012, Pages 570-579

  Lötvall, Jan ^a   Bateman, Eric D ^b   Bleecker, Eugene R ^c   Busse, William W ^d   Woodcock, Ashley ^e   Follows, Richard ^f   Lim, Jessica ^f   Stone, Sally ^f   Jacques, Loretta ^f   Haumann, Brett ^f  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Add on therapy; Asthma management; Bronchodilator

Indexed keywords

CORTICOSTEROID; PLACEBO; VILANTEROL TRIFENATATE;

ADULT; ARTICLE; ASTHMA; BACKACHE; BRONCHODILATATION; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EVENING DOSAGE; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOSE BLOOD LEVEL; HEART PALPITATION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE SPASM; OPTIMAL DRUG DOSE; PEAK EXPIRATORY FLOW; POWDER INHALER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION; TREMOR; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; BENZYL ALCOHOLS; CHLOROBENZENES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; RESPIRATORY FUNCTION TESTS; YOUNG ADULT;

EID: 84865814799     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00121411     Document Type: Article

References (30)

1. Busse WW, Lemanske RF Jr. Asthma. N Engl J Med 2001; 344: 350-362. (Pubitemid 32107645)
2. Tattersfield AE, Knox AJ, Britton JR, et al. Asthma. Lancet 2002; 360: 1313-1322. (Pubitemid 35284626)
3. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. www.ginasthma.org. Date last accessed: July 1, 2011. Date last updated: December 2010.
4. Dean BB, Calimlim BM, Kindermann SL, et al. The impact of uncontrolled asthma on absenteeism and health-related quality of life. J Asthma 2009; 46: 861-866.
5. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004; 170: 836-844. (Pubitemid 39346477)
6. Jones CA, Clement LT, Morphew T, et al. Achieving and maintaining asthma control in an urban pediatric disease management program: the Breathmobile Program. J Allergy Clin Immunol 2007; 119: 1445-1453. (Pubitemid 46863370)
7. Halterman JS, Auinger P, Conn KM, et al. Inadequate therapy and poor symptom control among children with asthma: findings from a multistate sample. Ambul Pediatr 2007; 7: 153-159. (Pubitemid 46395187)
8. Fueyo A, Ruiz MA, Ancochea J, et al. Asthma control in Spain. Do season and treatment pattern matter? The ESCASE study. Respir Med 2007; 101: 919-924. (Pubitemid 46505995)
9. Ducharme FM, Ni Chroinin M, Greenstone I, et al. Addition of long-acting β2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst Rev 2010; 5: CD005535.
10. Pauwels RA, Löfdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337: 1405-1411.
11. Masoli M, Weatherall M, Holt S, et al. Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma. Thorax 2005; 60: 730-734. (Pubitemid 41297891)
12. Axelsson M, Emilsson M, Brink E, et al. Personality, adherence, asthma control and health-related quality of life in young adult asthmatics. Respir Med 2009; 103: 1033-1040.
13. Stoloff SW, Stempel DA, Meyer J, et al. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol 2004; 113: 245-251. (Pubitemid 38210545)
14. van den Berge M, Luijk B, Bareille P, et al. Prolonged protection of the new inhaled corticosteroid fluticasone furoate against AMP hyperresponsiveness in patients with asthma. Allergy 2010; 65: 1531-1535.
15. Barrett VJ, Morrison V, Sturton RG, et al. Pharmacological characterisation of GW642444, a long-acting β2-agonist (LABA) with rapid onset and long duration, on isolated large and small human airways. Am J Respir Crit Care Med 2010; 181: A4453.
16. Barrett VJ, Emmons A, Ford AJ, et al. In vitro pharmacological characterisation of GW642444, a novel long acting β2-agonist using human recombinant β1/2/3 adrenoceptor cAMP assays. Am J Respir Crit Care Med 2010; 181: A4451.
17. Lötvall J, Bateman ED, Bleecker ER, et al. Dose-related efficacy of vilanterol trifenatate (VI), a long-acting β2 agonist (LABA) with inherent 24-hour activity, in patients with persistent asthma. Eur Respi J 2010; 36: Suppl. S4, 1013s.
18. Lötvall J, Bateman ED, Bleecker ER, et al. Four weeks' treatment with the novel long-acting β2 agonist (LABA) vilanterol trifenatate (VI) in asthma - evaluation of safety and maintained efficacy of albuterol. Am J Respir Crit Care Med 2011; 183: A4491.
19. National Institutes of Health. Guidelines for the Diagnosis and Management of Asthma (EPR-3) 2007. Bethesda, NHLBI, 2007.
20. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999; 159: 179-187. (Pubitemid 29036522)
21. Woodcock A, Bateman ED, Busse WW, et al. Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial. Respir Res 2011; 12: 132.
22. Rabe KF, Jörres R, Nowak D, et al. Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma. Am Rev Respir Dis 1993; 147: 1436-1441.
23. Lötvall J, Langley S, Woodcock A. Inhaled steroid/long-acting β2 agonist combination products provide 24 hours improvement in lung function in adult asthmatic patients. Respir Res 2006; 7: 110.
24. Berger WE, Bleecker ER, O'Dowd L, et al. Efficacy and safety of budesonide/formoterol pressurized metered-dose inhaler: randomized controlled trial comparing once- and twice-daily dosing in patients with asthma. Allergy Asthma Proc 2010; 31: 49-59.
25. Weatherall M, Wijesinghe M, Perrin K, et al. Long-acting β-agonists and asthma death: how useful are different study designs to evaluate the potential association? J Asthma 2010; 47: 434-438.
26. Weatherall M, Wijesinghe M, Perrin K, et al. Meta-analysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy. Thorax 2010; 65: 39-43.
27. Ullman A, Svedmyr N. Salmeterol, a new long acting inhaled β2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients. Thorax 1988; 43: 674-678.
28. Palmqvist M, Persson G, Lazer L, et al. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 1997; 10: 2484-2489. (Pubitemid 28048620)
29. Smolensky MH, Barnes PJ, Reinberg A, et al. Chronobiology and asthma. I. Day-night differences in bronchial patency and dyspnea and circadian rhythm dependencies. J Asthma 1986; 23: 321-343. (Pubitemid 17130982)
30. Martin RJ. Nocturnal asthma: circadian rhythms and therapeutic interventions. Am Rev Respir Dis 1993; 147: S25-S28. (Pubitemid 23156789)